$1.45
11.04% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US45781K2042
Symbol
IPHA
Sector
Industry

Innate Pharma - ADR Stock price

$1.45
-0.35 19.44% 1M
-1.45 50.02% 6M
-1.35 48.21% YTD
-1.05 42.00% 1Y
-3.28 69.34% 3Y
-4.51 75.67% 5Y
-4.60 76.03% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.18 11.04%
ISIN
US45781K2042
Symbol
IPHA
Sector
Industry

Key metrics

Market capitalization $117.38m
Enterprise Value $57.04m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.12
P/S ratio (TTM) P/S ratio 4.37
P/B ratio (TTM) P/B ratio 3.80
Revenue growth (TTM) Revenue growth -42.35%
Revenue (TTM) Revenue $26.87m
EBIT (operating result TTM) EBIT $-51.38m
Free Cash Flow (TTM) Free Cash Flow $-19.90m
EPS (TTM) EPS $-0.46
P/E forward 6.22
P/S forward 2.48
EV/Sales forward 1.20
Short interest 0.14%
Show more

Is Innate Pharma - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Innate Pharma - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Innate Pharma - ADR forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Innate Pharma - ADR forecast:

Buy
83%
Hold
17%

Financial data from Innate Pharma - ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
27 27
42% 42%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 16 16
29% 29%
60%
- Research and Development Expense 56 56
0% 0%
210%
-49 -49
70% 70%
-181%
- Depreciation and Amortization 2.80 2.80
56% 56%
10%
EBIT (Operating Income) EBIT -51 -51
47% 47%
-191%
Net Profit -37 -37
42% 42%
-137%

In millions USD.

Don't miss a Thing! We will send you all news about Innate Pharma - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Innate Pharma - ADR Stock News

Neutral
Seeking Alpha
about 20 hours ago
Innate has a stable of interesting pipeline projects in development for a range of cancers. The most advanced candidate is poised for a potential accelerated approval for cutaneous T-cell lymphoma. Other programs, including those partnered with big pharma, are beginning to show signs of promise in non-heme malignancies as well.
Neutral
Business Wire
6 days ago
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2025 financial calendar: March 27, 2025: Publication of 2024 financial statements May 13, 2025: Publication of revenue and cash position for 1Q2025 May 22, 2025: Annual General Shareholders Meeting September 17, 2025: Publication of ha...
Neutral
Business Wire
7 days ago
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the publication in Science Immunology of preclinical data demonstrating the potential of IPH6501, Innate's proprietary NK cell engager including an IL-2v and targeting CD20 from the ANKET® platform. IPH6501 is currently evaluated in a Pha...
More Innate Pharma - ADR News

Company Profile

Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells. The company was founded by Hervé Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié and François Romagné on September 15, 1999 and is headquartered in Marseille, France.

Head office France
CEO Jonathan Dickinson
Employees 179
Founded 1999
Website www.innate-pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today